Si Shi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5579159/publications.pdf

Version: 2024-02-01

76 papers	4,874 citations	126907 33 h-index	110387 64 g-index
77 all docs	77 docs citations	77 times ranked	5947 citing authors

#	Article	IF	Citations
1	Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Molecular Cancer, 2021, 20, 131.	19.2	702
2	Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. Journal of Hematology and Oncology, 2020, 13, 110.	17.0	698
3	Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Nature Genetics, 2016, 48, 747-757.	21.4	237
4	Applications of single-cell sequencing in cancer research: progress and perspectives. Journal of Hematology and Oncology, 2021, 14, 91.	17.0	172
5	The microbiota and microbiome in pancreatic cancer: more influential than expected. Molecular Cancer, 2019, 18, 97.	19.2	169
6	PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Molecular Cancer, 2020, 19, 49.	19.2	145
7	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Theranostics, 2018, 8, 5072-5087.	10.0	139
8	FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Redox Biology, 2021, 38, 101807.	9.0	135
9	ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Research, 2015, 25, 561-573.	12.0	112
10	Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Experimental and Molecular Medicine, 2017, 49, e406-e406.	7.7	108
11	ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Letters, 2016, 374, 127-135.	7.2	104
12	A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Theranostics, 2020, 10, 3967-3979.	10.0	103
13	Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut, 2020, 69, 888-900.	12.1	99
14	Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3Î²/Snail signaling. Oncogene, 2018, 37, 5843-5857.	5.9	92
15	A novel epigenetic CREBâ€miRâ€373 axis mediates ZIP4â€induced pancreatic cancer growth. EMBO Molecular Medicine, 2013, 5, 1322-1334.	6.9	88
16	Combinational therapy: New hope for pancreatic cancer?. Cancer Letters, 2012, 317, 127-135.	7.2	85
17	TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. Autophagy, 2020, 16, 486-500.	9.1	73
18	Ferroptosis: Final destination for cancer?. Cell Proliferation, 2020, 53, e12761.	5.3	73

#	Article	IF	Citations
19	FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 3950-3960.	7.0	72
20	Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2019, 269, 944-950.	4.2	71
21	LSD1 sustains pancreatic cancer growth via maintaining HIF1Î±-dependent glycolytic process. Cancer Letters, 2014, 347, 225-232.	7.2	63
22	The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. PeerJ, 2020, 8, e9602.	2.0	62
23	Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer. Nano Letters, 2019, 19, 3527-3534.	9.1	55
24	Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1Î± axis. Molecular Cancer, 2014, 13, 187.	19.2	54
25	The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Molecular Cancer, 2019, 18, 184.	19.2	54
26	The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer. Annals of Translational Medicine, 2020, 8, 1347-1347.	1.7	53
27	Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. Briefings in Bioinformatics, 2022, 23, .	6.5	47
28	ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. Cancer Letters, 2017, 388, 303-311.	7.2	46
29	Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Research, 2017, 15, 201-212.	3.4	45
30	TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1Î± axis and indicates prognosis in pancreatic cancer. Cell Death and Disease, 2018, 9, 321.	6.3	45
31	New insights into perineural invasion of pancreatic cancer: More than pain. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 111-122.	7.4	39
32	Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. Pancreatology, 2014, 14, 295-301.	1.1	38
33	Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Letters, 2015, 360, 227-233.	7.2	37
34	GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. Cell Death and Disease, 2018, 9, 1187.	6.3	37
35	Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. International Journal of Oncology, 2013, 42, 979-984.	3.3	36
36	Hexokinase 2 dimerization and interaction with voltageâ€dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. Cancer Medicine, 2019, 8, 5903-5915.	2.8	34

#	Article	IF	Citations
37	A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. , 2019, 7, 233.		34
38	Pin1 promotes pancreatic cancer progression and metastasis by activation of NFâ€ºBâ€ºLâ€›18 feedback loop. Cell Proliferation, 2020, 53, e12816.	5.3	32
39	Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. Cellular and Molecular Life Sciences, 2018, 75, 1001-1012.	5.4	31
40	microRNA signature for human pancreatic cancer invasion and metastasis. Experimental and Therapeutic Medicine, 2012, 4, 181-187.	1.8	30
41	Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition. Hepatobiliary and Pancreatic Diseases International, 2014, 13, 386-394.	1.3	30
42	Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. International Journal of Molecular Sciences, 2021, 22, 10944.	4.1	30
43	Emerging roles of the solute carrier family in pancreatic cancer. Clinical and Translational Medicine, 2021, 11, e356.	4.0	29
44	The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives. Journal of Hematology and Oncology, 2020, 13, 154.	17.0	28
45	Critical role of oncogenic KRAS in pancreatic cancer (Review). Molecular Medicine Reports, 2016, 13, 4943-4949.	2.4	27
46	Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochimica Et Biophysica Sinica, 2016, 48, 969-979.	2.0	24
47	FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Oncology Reports, 2017, 38, 2069-2077.	2.6	23
48	MiRâ€29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. International Journal of Cancer, 2018, 143, 2919-2931.	5.1	23
49	<scp>dCK</scp> negatively regulates the <scp>NRF</scp>2/<scp>ARE</scp> axis and <scp>ROS</scp> production in pancreatic cancer. Cell Proliferation, 2018, 51, e12456.	5.3	22
50	Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: ÂÂprospective randomized trial. Surgery, 2015, 158, 1211-1218.	1.9	21
51	Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Oncogene, 2020, 39, 6572-6588.	5.9	21
52	RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. Oncogene, 2022, 41, 2860-2872.	5.9	21
53	Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Cancer Cell International, 2019, 19, 49.	4.1	19
54	Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 177-188.	7.4	18

#	Article	IF	Citations
55	Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Cancer Cell International, 2021, 21, 196.	4.1	18
56	Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. European Journal of Surgical Oncology, 2019, 45, 1069-1076.	1.0	17
57	Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance. Cancers, 2019, 11, 1998.	3.7	17
58	SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Cancer Letters, 2021, 499, 265-278.	7.2	16
59	Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. American Journal of Cancer Research, 2020, 10, 1182-1193.	1.4	16
60	Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases. World Journal of Gastroenterology, 2018, 24, 3677-3680.	3.3	15
61	Differentiation of solid-pseudopapillary tumors of the pancreas from pancreatic neuroendocrine tumors by using endoscopic ultrasound. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 947-953.	1.5	14
62	Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features. Bioengineered, 2021, 12, 3593-3602.	3.2	10
63	Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. International Journal of Biological Sciences, 2021, 17, 2666-2682.	6.4	10
64	FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. American Journal of Cancer Research, 2019, 9, 2650-2664.	1.4	10
65	Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer. Experimental Hematology and Oncology, 2020, 9, .	5.0	7
66	Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). Hepatobiliary and Pancreatic Diseases International, 2021, 20, 163-172.	1.3	7
67	SETD8 induces stemness and epithelial–mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. Acta Biochimica Et Biophysica Sinica, 2021, 53, 1614-1624.	2.0	7
68	Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Oncogenesis, 2022, 11, .	4.9	7
69	Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. OncoTargets and Therapy, 2018, Volume 11, 4591-4608.	2.0	6
70	Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. Frontiers in Oncology, 2021, 11, 640820.	2.8	5
71	FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Acta Biochimica Et Biophysica Sinica, 2021, 53, 997-1008.	2.0	5
72	Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: Randomized controlled trials are needed. Journal of Surgical Oncology, 2019, 120, 1284-1285.	1.7	1

#	Article	IF	Citations
73	AJCC 8th edition staging system for pancreatic ductal adenocarcinoma: A controversial step forward?. European Journal of Surgical Oncology, 2020, 46, 703.	1.0	1
74	The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. Journal of Surgical Oncology, 2019, 120, 1053-1054.	1.7	0
75	Validation and head-to-head comparison of four models for predicting malignancy of intraductal papillary mucinous neoplasm of the pancreas: A study based on endoscopic ultrasound findings. World Journal of Gastrointestinal Oncology, 2019, 11, 1043-1053.	2.0	0
76	The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. Journal of Oncology, 2022, 2022, 1-16.	1.3	0